Safety of human papillomavirus (HPV) vaccines: A review of the international experience so far

This publication has 31 references indexed in Scilit:

• Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
  The Lancet, 2007
• Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases
  New England Journal of Medicine, 2007
• Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
  New England Journal of Medicine, 2007
• Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18
  Vaccine, 2006
• Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
  The Lancet, 2006
• Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
  The Lancet Oncology, 2005
• Efficacy and other milestones for human papillomavirus vaccine introduction
  Vaccine, 2004
• Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
  The Lancet, 2004
• A Controlled Trial of a Human Papillomavirus Type 16 Vaccine
  New England Journal of Medicine, 2002
• Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
  The Journal of Pathology, 1999